GLP-1 receptor agonists show consistent promise for reducing alcohol addiction and dementia risk, while the widely publicized suicidality concern has not been confirmed by well-controlled studies — but safety in high-risk psychiatric patients remains unestablished.
No suicidality increase confirmedWell-controlled active-comparator studies found no increased suicidality risk with GLP-1 drugs, despite widely publicized initial concerns
What the researchers found
The review identifies a nuanced psychiatric profile for GLP-1 receptor agonists:
**Positive evidence:**
- Substance use disorders: consistent evidence for therapeutic benefit, particularly for alcohol use disorders
- Dementia: several cohort studies indicate reduced risk, suggesting neuroprotective effects
**Mixed evidence:**
- Depression and anxiety: conflicting results from large observational studies, largely due to confounding by indication and methodological differences
**Safety concerns addressed:**
- Suicidality: initial reports raised alarm, but well-controlled active-comparator studies found no increased risk. Initial findings were likely driven by methodological limitations
- Safety in high-risk psychiatric populations: not yet established
The overall profile suggests therapeutic potential but calls for caution in psychiatrically vulnerable patients.
Why it matters
With GLP-1 drugs prescribed to an unprecedented number of patients for diabetes and obesity, understanding their psychiatric effects is critical. The finding that these drugs may help with alcohol addiction could open a major new therapeutic avenue. Equally important is resolving the suicidality question — unfounded safety concerns could prevent patients from accessing beneficial treatment, while real risks in vulnerable populations must be identified and managed.
How the study worked
This is a narrative review summarizing current evidence on GLP-1 RAs' effects on psychiatric and neurocognitive conditions. The author evaluated observational studies, cohort studies, active-comparator analyses, and regulatory safety data across multiple mental health domains.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis, which may introduce selection bias. Much of the psychiatric evidence comes from observational studies with significant confounding factors — people taking GLP-1 drugs for diabetes/obesity differ systematically from controls. The conflicting depression/anxiety data may reflect that some patients improve (via weight loss-related quality of life) while others worsen (via biological mechanisms), making average effects misleading. Long-term psychiatric follow-up data are lacking.
How to read the evidence
This is a narrative review synthesizing evidence of varying quality. The substance use disorder and dementia findings are supported by multiple cohort studies but lack RCT confirmation. The suicidality finding draws on well-designed active-comparator studies. Overall, the evidence base is growing but requires dedicated psychiatric clinical trials for definitive conclusions.
When this study was published
Published in 2025, this review captures the most current understanding of GLP-1 drugs and mental health — a rapidly evolving topic with new studies published frequently. The conclusions reflect the state of evidence as of early 2025.
The bigger picture
The neuropsychiatric effects of GLP-1 drugs are among the most intensely debated topics in medicine today. These peptide drugs act on GLP-1 receptors found throughout the brain, particularly in reward centers and areas involved in cognitive function. As clinical trials specifically targeting addiction and dementia are launched, the psychiatric profile of GLP-1 drugs will likely become a major determining factor in their long-term clinical value beyond metabolic disease.
Questions still open
- Will dedicated randomized trials of GLP-1 drugs for alcohol use disorder confirm the consistent positive signal from observational studies?
- Are there specific psychiatric risk factors that clinicians should screen for before prescribing GLP-1 receptor agonists?
- Do the neuropsychiatric effects differ between GLP-1-only drugs and dual agonists like tirzepatide?
Common questions
Can GLP-1 drugs like semaglutide cause suicidal thoughts?
Could GLP-1 drugs help with alcohol addiction?
Read the original research
Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks.
Journal of Yeungnam medical science, 42, 61
Citation
Kim, JinWoo. (2025). Glucagon-like peptide-1 receptor agonists and mental health: a narrative review of emerging benefits and risks.. Journal of Yeungnam medical science, 42, 61. https://doi.org/10.12701/jyms.2025.42.61